Ascendis Pharma A/S vs Bank of New York Mellon Corp — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Bank of New York Mellon Corp trades at $161.36 (market cap $108.78B). The key difference: Bank of New York Mellon Corp is far larger — about 6.5× Ascendis Pharma A/S's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BNY | |
|---|---|---|
Market Cap | $16.67B | $108.78B |
Sector | Health | Financials |
52-Week High | $277.18 | $162.35 |
52-Week Low | $189.74 | $101.00 |
Enterprise Value | $17.04B | — |
Dividend Yield | — | 1.38% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →